Edition:
United States

Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

8.50USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$8.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
163,080
52-wk High
$20.25
52-wk Low
$7.34

Chart for

About

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in... (more)

Overall

Beta: 0.97
Market Cap(Mil.): $478.04
Shares Outstanding(Mil.): 57.05
Dividend: --
Yield (%): --

Financials

  AKBA.OQ Industry Sector
P/E (TTM): -- 109.17 32.55
EPS (TTM): -1.31 -- --
ROI: -33.78 1.47 12.80
ROE: -61.31 0.22 14.92

Ex-Akebia employee jailed for night as insider trading trial starts

BOSTON A former Akebia Therapeutics Inc employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday.

Jun 26 2018

CORRECTED-Ex-Akebia employee jailed for night as insider trading trial starts

BOSTON, June 26 A former Akebia Therapeutics Inc employee accused of engaging in an insider trading scheme must spend a night in jail after he violated a U.S. judge's order and spoke to a witness at the start of his trial on Tuesday.

Jun 26 2018

BRIEF-Akebia Therapeutics Reports Q1 Loss Per Share $0.48

* AKEBIA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

Earnings vs. Estimates